Drugs / Tetravalent live attenuated dengue vaccine
Tetravalent live attenuated dengue vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00322049 | Feb 2004 → Jun 2009 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetravalent live attenuated dengue vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00322049 ↗ |
| Known as | F17 | “DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines.” NCT00322049 ↗ |
| Known as | T-DEN F17 | “Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )” NCT00322049 ↗ |
| Modality | Vaccine | “tetravalent live attenuated dengue vaccine” NCT00322049 ↗ |
| Route | Subcutaneous | “for subcutaneous injection” NCT00322049 ↗ |